2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
02:45 p.m. - 04:15 p.m.
MCCNO - La Nouvelle C
Treatment Considerations, Combination Therapy, Biological Therapies, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Anticoagulant Drugs, Chemotherapy, Biological Processes, CHIP, Clinical Practice (Health Services and Quality), Value, Diseases, Lymphoid Malignancies, Plasma Cell Disorders, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult
PAPER

938 Population-level trends in first-month mortality in multiple myeloma (2000–2023): Declining rates, persistent age disparities, and racial discordance

Bakr Alhayek, MD, Michael Jaglal, MD2, Timothy Kubal, MD, MBA3, Muhammad Umair Mushtaq, MD4, Moazzam Shahzad, MD5
1 Adventhealth Tampa, Tampa, Florida, United States
2 Moffitt Cancer Center, Tampa, Florida, United States
3 Moffitt Cancer Center, Tampa, Florida, United States
4 Kansas University Medical Center, Kansas City, Kansas, United States
5 Moffitt Cancer Center, Tampa, Florida, United States

Background: Early mortality remains an unresolved problem in multiple myeloma (MM), despite marked improvements in therapeutic options over the past two decades. European registry analyses have documented declining early mortality through 2018, and US analyses through 2020, but both employed intervals of 6 to 24 months. Mortality within the first month of diagnosis has not been characterized at the US population level, and no published series extends into the immunotherapy era. Racial patterns likewise remain unsettled: Wei et al. (2024) reported higher 2-year early mortality among non-Hispanic Black (NHB) patients in SEER, leaving unresolved whether this disadvantage is present at presentation or arises subsequently.

Methods: We identified 107,465 patients in the SEER 17 Research Plus database with histologically confirmed MM (ICD-O-3 9732/3) as a first primary malignancy, diagnosed between 2000 and 2023. Because SEER records survival in integer months, mortality at 0 months was used to define the first-month endpoint; this measure approximates but is not equivalent to 30-day mortality. Two- and three-month mortality were calculated in parallel. Temporal trends were evaluated across three diagnostic periods (2000–2009, 2010–2017, 2018–2023) and by single year of diagnosis using logistic regression. A multivariable logistic model, with NH White as the reference category, was fitted to identify independent predictors of first-month mortality. Smoldering myeloma is estimated to account for approximately 11% of SEER MM cases (Huber et al., 2026, JNCI), which would bias the observed rates downward.

Results: Median age at diagnosis was 68 years (IQR 58–78), and 54.5% of the cohort was male. Mortality was 4.6% at one month (n=4,977), 7.9% at two months (n=8,450), and 10.4% at three months (n=11,132). First-month mortality declined from 5.7% in 2000–2009 to 4.3% in 2010–2017 and 3.9% in 2018–2023, a 32% relative reduction (p < 0.001). The annual trend was concordant, falling from 7.2% in 2000 to 3.3% in 2023 (OR per year 0.972, 95% CI 0.968–0.976; p < 0.001). The greatest absolute reduction occurred among the oldest patients: first-month mortality among those aged ≥80 declined from 12.4% to 9.7%, a 2.7 percentage-point decrease, compared with 1.8% to 0.9% among patients aged <50. Age was the strongest predictor in the multivariable model (≥80 vs <50: OR 7.95, 95% CI 6.56–9.63; p < 0.001). Male sex (OR 1.26) and separated, divorced, or widowed marital status (OR 1.47, vs married) were additional independent predictors.

Adjusted first-month mortality was lower among NHB patients than among non-Hispanic White (NHW) patients (OR 0.82, 95% CI 0.76–0.89; p < 0.001), and lower among non-Hispanic Asian/Pacific Islander patients (OR 0.83, 95% CI 0.73–0.94; p = 0.004). Hispanic and NHW patients did not differ (OR 0.97; p = 0.49). This direction of effect is opposite to that reported by Wei et al. (2024) at 2 years in the same registry, indicating that the racial survival gap in MM emerges after the immediate post-diagnostic interval and is more consistent with differential access to sustained therapy than with greater severity at presentation.

Conclusions: In the largest US analysis of first-month mortality in MM to date, mortality declined 32% between 2000–2009 and 2018–2023, with the trend continuing into the immunotherapy era. The burden nonetheless persists: approximately 1 in 22 patients dies within one month of diagnosis, and 1 in 10 among those aged ≥80. The observed reversal by race, in which NHB patients had lower first-month mortality than would be predicted from the higher 2-year mortality reported previously, suggests that disparities arise between acute management and longitudinal care. Interpretation is constrained by the absence of cause-of-death, tumor biology, and treatment data; by the integer-month survival variable, which precludes an exact 30-day cutoff; and by probable dilution from smoldering disease within the registry. The first month after diagnosis constitutes a discrete interval of excess mortality and merits targeted intervention.

Bakr Alhayek, MD: No relevant conflicts of interest to declare.